You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Market News

Market News

HomeMarket NewsInformation about Individual Stocks

Innogen-B (02591)

Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in development of drugs. Its products are used for treatment of metabolic diseases, including diabetes, obesity, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China.